Chandler H. Park - Concepedia

Concepedia

Author

Chandler H. Park

Norton Healthcare

Also Known As

Chandler H Park, Chandler H. Park

45

Publications

2.6K

Citations

9

H-Index

20

Concepts

All Affiliations

Norton Healthcare Université Paris-Saclay Cornell University Institut Gustave Roussy Weill Cornell Medicine

CH

About

Chandler H. Park is an author at Norton Healthcare specializing in oncology, cancer therapeutics, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	161
2	Health Sciences	3	3	77
3	Immunology	3	3	77
4	Pharmacology	1	1	12
5	Radiation Medicine	1	1	72

Chandler H. Park

×

8

Publications

2.6K

Citations

8

H-Index

	Year	Citations
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Oliver Sartor, Johann S. de Bono, Kim N., New England Journal of Medicine	2021	2.3K
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). Michael J. Morris, Johann S. de Bono, Kim N., Journal of Clinical Oncology UrologyRadiation MedicinePsma-positive McrpcGenitourinary CancerPsma Positivity	2021	72
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3 Petros Grivas, Damien Pouessel, Chandler H. Park, Journal of Clinical Oncology	2024	64
TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. Petros Grivas, Damien Pouessel, Chandler H. Park, Journal of Clinical Oncology Cancer ManagementImmunologyImmunotherapeuticsImmunotherapyMetastatic Urothelial Cancer	2022	35
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. Daniel P. Petrylak, Scott T. Tagawa, Rohit Jain, Journal of Clinical Oncology Preclinical TherapeuticsImmunologyPrior TherapiesPrior Checkpoint InhibitorImmunotherapeutics	2023	22
Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. Petros Grivas, Damien Pouessel, Chandler H. Park, Journal of Clinical Oncology ImmunologyPharmacotherapyImmunotherapeuticsImmunotherapyPre-clinical Pharmacology	2023	20
Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. Matthew R. Smith, Maha Hussain, Fred Saad, Journal of Clinical Oncology Arasens TrialUrologyDaro ArmGenitourinary CancerMedicine	2022	12
Reviewing the Landscape of Cancer Survivorship: Insights from Dr. Lidia Schapira’s Programs and Beyond Viviana Cortiana, Rabab Hunaid Abbas, Soumiya Nadar, Cancers	2024	10

Page 1